Akademska digitalna zbirka SLovenije - logo
E-viri
Preverite dostopnost
Recenzirano
  • Corleis, Björn; Tzouanas, Constantine N; Wadsworth, 2nd, Marc H; Cho, Josalyn L; Linder, Alice H; Schiff, Abigail E; Zessin, Björn; Stei, Fabian; Dorhoi, Anca; Dickey, Amy K; Medoff, Benjamin D; Shalek, Alex K; Kwon, Douglas S

    Science translational medicine, 12/2023, Letnik: 15, Številka: 725
    Journal Article

    Tobacco smoking doubles the risk of active tuberculosis (TB) and accounts for up to 20% of all active TB cases globally. How smoking promotes lung microenvironments permissive to ( ) growth remains incompletely understood. We investigated primary bronchoalveolar lavage cells from current and never smokers by performing single-cell RNA sequencing (scRNA-seq), flow cytometry, and functional assays. We observed the enrichment of immature inflammatory monocytes in the lungs of smokers compared with nonsmokers. These monocytes exhibited phenotypes consistent with recent recruitment from blood, ongoing differentiation, increased activation, and states similar to those with chronic obstructive pulmonary disease. Using integrative scRNA-seq and flow cytometry, we identified CD93 as a marker for a subset of these newly recruited smoking-associated lung monocytes and further provided evidence that the recruitment of monocytes into the lung was mediated by CCR2-binding chemokines, including CCL11. We also show that these cells exhibit elevated inflammatory responses upon exposure to and accelerated intracellular growth of compared with mature macrophages. This elevated growth could be inhibited by anti-inflammatory small molecules, providing a connection between smoking-induced pro-inflammatory states and permissiveness to growth. Our findings suggest a model in which smoking leads to the recruitment of immature inflammatory monocytes from the periphery to the lung, which results in the accumulation of these -permissive cells in the airway. This work defines how smoking may lead to increased susceptibility to and identifies host-directed therapies to reduce the burden of TB among those who smoke.